Andrew L Hopkins

List of Publications by Year
in descending order

44 papers	18,078 citations	172457 29 h-index	276875 41 g-index
47 all docs	47 docs citations	47 times ranked	20863 citing authors

#	Article	IF	Citations
1	Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology, 2008, 4, 682-690.	8.0	3,165
2	How many drug targets are there?. Nature Reviews Drug Discovery, 2006, 5, 993-996.	46.4	3,073
3	The druggable genome. Nature Reviews Drug Discovery, 2002, 1, 727-730.	46.4	2,918
4	Ligand efficiency: a useful metric for lead selection. Drug Discovery Today, 2004, 9, 430-431.	6.4	1,687
5	Quantifying the chemical beauty of drugs. Nature Chemistry, 2012, 4, 90-98.	13.6	1,194
6	Network pharmacology. Nature Biotechnology, 2007, 25, 1110-1111.	17.5	933
7	The role of ligand efficiency metrics in drug discovery. Nature Reviews Drug Discovery, 2014, 13, 105-121.	46.4	849
8	Global mapping of pharmacological space. Nature Biotechnology, 2006, 24, 805-815.	17.5	776
9	Automated design of ligands to polypharmacological profiles. Nature, 2012, 492, 215-220.	27.8	698
10	Can we rationally design promiscuous drugs?. Current Opinion in Structural Biology, 2006, 16, 127-136.	5.7	472
11	Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. Journal of Medicinal Chemistry, 1996, 39, 1589-1600.	6.4	353
12	Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Reviews Drug Discovery, 2008, 7, 900-907.	46.4	282
13	Predicting promiscuity. Nature, 2009, 462, 167-168.	27.8	165
14	Fragment Screening by Surface Plasmon Resonance. ACS Medicinal Chemistry Letters, 2010, 1, 44-48.	2.8	134
15	Design of MKC-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV Mutants. Journal of Medicinal Chemistry, 1999, 42, 4500-4505.	6.4	130
16	Validity of Ligand Efficiency Metrics. ACS Medicinal Chemistry Letters, 2014, 5, 616-618.	2.8	112
17	A crowdsourcing evaluation of the NIH chemical probes. Nature Chemical Biology, 2009, 5, 441-447.	8.0	111
18	Crystal Structures of HIV-1 Reverse Transcriptase in Complex with Carboxanilide Derivativesâ€,â€¡. Biochemistry, 1998, 37, 14394-14403.	2.5	97

#	Article	IF	Citations
19	Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. PLoS Neglected Tropical Diseases, 2012, 6, e1762.	3.0	93
20	Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.. Journal of Medicinal Chemistry, 2004, 47, 5912-5922.	6.4	87
21	Screening for GPCR Ligands Using Surface Plasmon Resonance. ACS Medicinal Chemistry Letters, 2011, 2, 549-554.	2.8	81
22	3â€²-Azido-3â€²-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9518-9523.	7.1	71
23	Discovery of Î²2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Medicinal Chemistry Letters, 2013, 4, 1005-1010.	2.8	65
24	Fragment screening by SPR and advanced application to GPCRs. Progress in Biophysics and Molecular Biology, 2014, 116, 113-123.	2.9	63
25	Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.. Journal of Medicinal Chemistry, 2004, 47, 5923-5936.	6.4	61
26	The Joint European Compound Library: boosting precompetitive research. Drug Discovery Today, 2015, 20, 181-186.	6.4	59
27	Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Medicinal Chemistry, 2011, 3, 1809-1820.	2.3	53
28	Crystallographic Analysis of the Binding Modes of Thiazoloisoindolinone Non-Nucleoside Inhibitors to HIV-1 Reverse Transcriptase and Comparison with Modeling Studies. Journal of Medicinal Chemistry, 1999, 42, 3845-3851.	6.4	42
29	Mission possible. Nature, 2007, 449, 166-169.	27.8	41
30	Application of RNAi to Genomic Drug Target Validation in Schistosomes. PLoS Neglected Tropical Diseases, 2015, 9, e0003801.	3.0	33
31	Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Scientific Reports, 2021, 11, 13208.	3.3	24
32	Know your chemical space. Nature Chemical Biology, 2010, 6, 482-483.	8.0	23
33	Surface Plasmon Resonance Analysis of Seven-Transmembrane Receptors. Methods in Enzymology, 2015, 556, 499-525.	1.0	23
34	An ontology for description of drug discovery investigations. Journal of Integrative Bioinformatics, 2010, 7, .	1.5	22
35	Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening. ACS Medicinal Chemistry Letters, 2016, 7, 1213-1218.	2.8	18
36	Protein kinase drugs â€“ optimism doesn't wait on facts â–¾. Drug Discovery Today, 2002, 7, 801-802.	6.4	15

#	Article	IF	Citations
37	Rapid Analysis of Pharmacology for Infectious Diseases. Current Topics in Medicinal Chemistry, 2011, 11, 1292-1300.	2.1	15
38	An Ontology for Description of Drug Discovery Investigations. Journal of Integrative Bioinformatics, 2010, 7, .	1.5	13
39	Structural Bioinformatics in Drug Discovery. Methods of Biochemical Analysis, 2005, 44, 477-497.	0.2	9
40	Knowledge and Intelligence in Drug Design. Annual Reports in Medicinal Chemistry, 2006, , 425-437.	0.9	7
41	Surveying GPCR solubilisation conditions using surface plasmon resonance. Analytical Biochemistry, 2018, 556, 23-34.	2.4	5
42	Pharmacological Space. , 2008, , 521-532.		4
43	Pharmacological Space. , 2008, , 395-408.		0
44	Editorial [Hot Topic: Progress in Neglected Disease Drug Discovery (Guest Editors: Andrew L. Hopkins) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.1	0